Klingenstein Fields Portfolio Changes in Q2 2026: Strategic Shifts and Key Transactions

Klingenstein Fields & Co Lp Q2 Activity Overview

According to data available on Insider Set, Klingenstein Fields & Co Lp experienced notable changes in its portfolio holdings during the second quarter of 2026.

The investor, known for active management, saw significant buying activity concentrated within exchange-traded funds (ETFs) and specific individual stocks. Notable purchases included substantial increases in shares held of XLK, the Select Sector SPDR Trust focused on technology, as well as significant additions to positions in other ETFs like SOXX (the iShares Semiconductor ETF) and FNDX (Schwab Strategic Trust). Individual stock purchases were also evident in the case of PLTR, Palantir Technologies Inc.

In contrast to these buys, Klingenstein Fields & Co Lp divested significant portions of its holdings during Q2. The most prominent exits involved ZS, Zscaler Inc., where they sold nearly all shares (-98.35% reduction), and REGN, Regeneron Pharmaceuticals Inc., which saw a substantial decrease in holdings.

Additionally, the investor made smaller adjustments to other positions like SCHF (Schwab Strategic Trust) and SCHA. On the individual stock front, they also sold shares of LLY, Eli Lilly and Company.

The portfolio's structure remains heavily weighted towards Technology stocks, which account for approximately 24% allocation as per Insider Set data. Other significant sectors include Healthcare and Financial Services.

Klingenstein Fields & Co Lp's Q2 activity demonstrates a clear focus on ETFs, particularly those tracking technology and semiconductors, alongside targeted individual stock investments like Palantir Technologies Inc (PLTR). Their strategy also involved sharp reductions in certain positions, notably Zscaler Inc (ZS) and Regeneron Pharmaceuticals Inc (REGN).